Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HHAT | Q5VTY9 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LHCGR | P22888 | 8/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2308890 | 0.86 | HHAT (0.56) | HHATLHCGRSTAT3 | |
| SCHEMBL2307641 | 0.83 | LHCGR (0.51) | HHATLHCGR | |
| SCHEMBL2304700 | 0.83 | LHCGR (0.58) | HHATLHCGR | |
| SCHEMBL2309732 | 0.83 | LHCGR (0.51) | LHCGR | |
| SCHEMBL2308391 | 0.83 | HHAT (0.56) | HHATLHCGR | |
| SCHEMBL2306710 | 0.82 | HHAT (0.52) | HHATLHCGR | |
| SCHEMBL2307619 | 0.82 | HHAT (0.57) | HHATLHCGRSTAT3 | |
| SCHEMBL2304926 | 0.82 | HHAT (0.55) | HHATKMT2ALHCGRSTAT3 | |
| SCHEMBL2308092 | 0.81 | HHAT (0.54) | HHATLHCGR | |
| SCHEMBL2308017 | 0.81 | HHAT (0.58) | HHATLHCGRSTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350093-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDROTHIENOPYRIDINES AS KCNQ2/3 MODULATORS FOR TREATING PAIN, EPILEPSY AND URINARY INCONTINENCE | GRUENENTHAL GMBH (DE) | 2012-10-03 | — | — | EP | claimed |
| EP-2350093-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROTHIENOPYRIDINES AS KCNQ2/3 MODULATORS FOR TREATING PAIN, EPILEPSY AND URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2011-08-03 | — | — | EP | claimed |
| WO-2010046108-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROTHIENOPYRIDINES AS KCNQ2/3 MODULATORS FOR TREATING PAIN, EPILEPSY AND URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2010-04-29 | — | — | WO | claimed |
| US-20100105722-A1 | Substituted 4,5,6,7-tetrahydrothienopyridines as KCNQ2/3 Modulators | GRUENENTHAL GMBH (DE) | 2010-04-29 | — | — | US | claimed |
| EP-2350093-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDROTHIENOPYRIDINES AS KCNQ2/3 MODULATORS FOR TREATING PAIN, EPILEPSY AND URINARY INCONTINENCE | GRUENENTHAL GMBH (DE) | 2012-10-03 | — | — | EP | disclosed |
| EP-2350093-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROTHIENOPYRIDINES AS KCNQ2/3 MODULATORS FOR TREATING PAIN, EPILEPSY AND URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010046108-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROTHIENOPYRIDINES AS KCNQ2/3 MODULATORS FOR TREATING PAIN, EPILEPSY AND URINARY INCONTINENCE | Grünenthal GmbH (DE) | 2010-04-29 | — | — | WO | disclosed |
| US-20100105722-A1 | Substituted 4,5,6,7-tetrahydrothienopyridines as KCNQ2/3 Modulators | GRUENENTHAL GMBH (DE) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105722-A1 | Substituted 4,5,6,7-tetrahydrothienopyridines as KCNQ2/3 Modulators | KCNQ1, KCNQ3, KCNQ2 | HHAT 3956/4885ALDH1A1 2284/4885KMT2A 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.